Form 8-K - Current report:
SEC Accession No. 0001104659-25-107353
Filing Date
2025-11-06
Accepted
2025-11-06 07:01:23
Documents
14
Period of Report
2025-11-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acrs-20251106x8k.htm   iXBRL 8-K 40398
2 EX-99.1 acrs-20251106xex99d1.htm EX-99.1 193146
3 GRAPHIC acrs-20251106xex99d1001.jpg GRAPHIC 5588
  Complete submission text file 0001104659-25-107353.txt   367397

Data Files

Seq Description Document Type Size
4 EX-101.SCH acrs-20251106.xsd EX-101.SCH 2684
5 EX-101.LAB acrs-20251106_lab.xml EX-101.LAB 15915
6 EX-101.PRE acrs-20251106_pre.xml EX-101.PRE 10222
16 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20251106x8k_htm.xml XML 4840
Mailing Address 701 LEE ROAD SUITE 103 WAYNE PA 19087
Business Address 701 LEE ROAD SUITE 103 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

EIN.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37581 | Film No.: 251456062
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)